Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel pharmaceutical composition for diabetes prevention and treatment

A composition and diabetes technology, applied in the direction of drug combination, metabolic diseases, etc., can solve the problems of increasing the frequency of bladder cancer, improving the cardiovascular system, etc., achieve excellent hypoglycemic effect, reduce side effects, and excellent insulin resistance improvement effect Effect

Inactive Publication Date: 2014-05-07
王松
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, pioglitazone is known to have a side effect of increasing the incidence of bladder cancer during treatment (Non-Patent Document 3)
On the other hand, rosiglitazone is known to have a side effect of increasing the risk of the cardiovascular system (Non-Patent Document 4)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] tablet

[0040] Use the composition of kind and amount shown in Table 1, obtain the pharmaceutical composition (tablet) containing pioglitazone:rosiglitazone=6:4 according to the following method.

[0041] Lactose (excipient) and croscarmellose sodium (Ac-Di-Sol: disintegrant) were added to pioglitazone and rosiglitazone, and mixed using a high-speed stirring granulator. To this mixture, an aqueous solution of hydroxypropylcellulose (binder) was added and mixed to obtain a granulated product. The granulated matter is dried with a fluidized bed dryer, and then the dried granulated matter is forcibly passed through a sieve using a crushing and granulating granulator, and then magnesium stearate (lubricant) is added, and a V-type mixer is used to to mix. The mixture was molded using a pestle with a diameter of 7 mm, and an aqueous solution of OPADRY WHITE (coating agent) in which yellow ferric oxide (pigment) was dispersed was sprayed on the molded product using a coat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention aims to research a combined treatment of pioglitazone and rosiglitazone, and relate to a novel pharmaceutical composition for diabetes prevention and treatment which has an excellent function of PPAR excitation (activation) and which alleviate side effects at the same time. The PPAR excitation function can be maintained by giving the pioglitazone and rosiglitazone, preparations of acceptable slat thereof in the pharmacology, or alternatively giving the abovementioned single dosages and the acceptable slat thereof in the pharmacology. The novel pharmaceutical composition has an excellent insulin resistance function and an excellent hypoglycemic effect, and can alleviate side effects when being used as a single dosage.

Description

technical field [0001] The present invention relates to an effective drug for improving insulin resistance with reduced side effects, excellent PPAR (peroxisome proliferator-activated receptor, Peroxisome Proliferator-Activated Receptor) activating (agonistic) action, and insulin resistance improving action Composition, that is, a pharmaceutical composition for the prevention and treatment of diabetes and its administration method. Background technique [0002] Currently, it is known that PPAR-activating drugs such as thiazolidine-based compounds and oxazolidine-based compounds are effective as therapeutic drugs for various diseases such as diabetes and hyperlipidemia (Non-Patent Documents 1 and 2). Among them, Actos (pioglitazone hydrochloride (Pioglitazone: 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl]thiazolidine-2,4-dione)) and Auandia (Malaysian Rosiglitazone toate (Rosiglitazone: 5-[4-[2-{N-methyl-N-(2-pyridyl)amino}ethoxy]benzyl]thiazolidine-2,4-dione) ) has been used...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4439A61P3/10
Inventor 藤田岳
Owner 王松
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com